Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.45 |
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
| ▸ | PLK1 | P53350 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 2/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786625 | 0.88 | CCNA2 (0.41) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL6792298 | 0.76 | CCNA2 (0.43) | CDK2CCNA2CCNA1RAB9A | |
| SCHEMBL6790555 | 0.73 | CCNA2 (0.40) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL6794887 | 0.73 | CCNA2 (0.41) | CDK2CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL6794519 | 0.70 | CCNA2 (0.80) | CDK2CCNA2CCNA1 | |
| SCHEMBL6790548 | 0.70 | CCNA2 (0.37) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL6794542 | 0.69 | CCNA2 (0.40) | CDK2CCNA2CCNA1BRD4 | |
| SCHEMBL6792545 | 0.64 | CDK4 (0.36) | CDK2CCNA2CCNA1RAB9A | |
| SCHEMBL6791026 | 0.64 | SMN1; SMN2 (0.42) | CDK2CCNA2CCNA1POLB | |
| SCHEMBL31429349 | 0.64 | LMNA (0.47) | CDK2CCNA2CCNA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CDK2 29/4885CCNA2 270/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.